Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market

Kymera Therapeutics Inc (NASDAQ:KYMR) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The company’s stock saw a pre-market decline of approximately 2.7%, reflecting investor disappointment with the results.

Key Financial Highlights vs. Estimates

• Revenue: Reported $11.48 million, down 55% year-over-year and significantly below the consensus estimate of $23.86 million.
• EPS: Posted a loss of $0.95 per share, worse than the estimated loss of $0.83.
• Full-Year Outlook: Analysts project full-year 2025 sales at $74.49 million, while revenue estimates remain negative at -$3.57 million. For Q3, expectations stand at $17.16 million in sales and an EPS loss of $0.92.

The revenue decline was notable, though the company did not provide explicit forward guidance in its press release. The market reaction suggests concerns over Kymera’s near-term financial performance, particularly given the widening losses.

Business and Clinical Updates

Despite the financial miss, Kymera highlighted progress in its clinical pipeline:

• KT-621 (STAT6): Positive Phase 1 data in healthy volunteers, surpassing the company’s target product profile. The drug candidate demonstrated an oral, dupilumab-like profile, potentially positioning it as a competitor in immunology and inflammation treatments.
• Pipeline Focus: The company continues advancing its targeted protein degradation (TPD) platform, Pegasus, with clinical programs in IRAK4, STAT3, and MDM2, targeting immuno-inflammatory diseases and oncology.

Market Reaction and Investor Sentiment

The stock’s pre-market dip aligns with the earnings miss, though the broader performance over the past month (-8.7%) and two weeks (-11.3%) indicates lingering skepticism. Investors appear to weigh the clinical progress against financial execution risks.

For a deeper dive into Kymera’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.